Skip to main content
Top
Published in: Journal of Translational Medicine 1/2020

Open Access 01-12-2020 | Severe Acute Respiratory Syndrome Coronavirus | Research

Emerging of a SARS-CoV-2 viral strain with a deletion in nsp1

Authors: Francesca Benedetti, Greg A. Snyder, Marta Giovanetti, Silvia Angeletti, Robert C. Gallo, Massimo Ciccozzi, Davide Zella

Published in: Journal of Translational Medicine | Issue 1/2020

Login to get access

Abstract

Background

The new Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which was first detected in Wuhan (China) in December of 2019 is responsible for the current global pandemic. Phylogenetic analysis revealed that it is similar to other betacoronaviruses, such as SARS-CoV and Middle-Eastern Respiratory Syndrome, MERS-CoV. Its genome is ∼ 30 kb in length and contains two large overlapping polyproteins, ORF1a and ORF1ab that encode for several structural and non-structural proteins. The non-structural protein 1 (nsp1) is arguably the most important pathogenic determinant, and previous studies on SARS-CoV indicate that it is both involved in viral replication and hampering the innate immune system response. Detailed experiments of site-specific mutagenesis and in vitro reconstitution studies determined that the mechanisms of action are mediated by (a) the presence of specific amino acid residues of nsp1 and (b) the interaction between the protein and the host’s small ribosomal unit. In fact, substitution of certain amino acids resulted in reduction of its negative effects.

Methods

A total of 17,928 genome sequences were obtained from the GISAID database (December 2019 to July 2020) from patients infected by SARS-CoV-2 from different areas around the world. Genomes alignment was performed using MAFFT (REFF) and the nsp1 genomic regions were identified using BioEdit and verified using BLAST. Nsp1 protein of SARS-CoV-2 with and without deletion have been subsequently modelled using I-TASSER.

Results

We identified SARS-CoV-2 genome sequences, from several Countries, carrying a previously unknown deletion of 9 nucleotides in position 686-694, corresponding to the AA position 241-243 (KSF). This deletion was found in different geographical areas. Structural prediction modelling suggests an effect on the C-terminal tail structure.

Conclusions

Modelling analysis of a newly identified deletion of 3 amino acids (KSF) of SARS-CoV-2 nsp1 suggests that this deletion could affect the structure of the C-terminal region of the protein, important for regulation of viral replication and negative effect on host’s gene expression. In addition, substitution of the two amino acids (KS) from nsp1 of SARS-CoV was previously reported to revert loss of interferon-alpha expression. The deletion that we describe indicates that SARS-CoV-2 is undergoing profound genomic changes. It is important to: (i) confirm the spreading of this particular viral strain, and potentially of strains with other deletions in the nsp1 protein, both in the population of asymptomatic and pauci-symptomatic subjects, and (ii) correlate these changes in nsp1 with potential decreased viral pathogenicity.
Literature
1.
go back to reference Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12:2.CrossRef Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12:2.CrossRef
2.
go back to reference Chan JF, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–36.CrossRef Chan JF, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–36.CrossRef
3.
go back to reference Li X, et al. Potential of large “first generation” human-to-human transmission of 2019-nCoV. J Med Virol. 2020;92(4):448–54.CrossRef Li X, et al. Potential of large “first generation” human-to-human transmission of 2019-nCoV. J Med Virol. 2020;92(4):448–54.CrossRef
4.
go back to reference Wang C, et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol. 2020;92(6):667–74.CrossRef Wang C, et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol. 2020;92(6):667–74.CrossRef
5.
go back to reference Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020;19:100682.CrossRef Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020;19:100682.CrossRef
6.
go back to reference Andersen KG, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–2.CrossRef Andersen KG, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–2.CrossRef
7.
go back to reference Wu A, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27(3):325–8.CrossRef Wu A, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27(3):325–8.CrossRef
8.
9.
go back to reference Adhikari SP, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Povert. 2020;9(1):29.CrossRef Adhikari SP, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Povert. 2020;9(1):29.CrossRef
10.
go back to reference Fu L, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020;80(6):656–65.CrossRef Fu L, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020;80(6):656–65.CrossRef
11.
go back to reference Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef
12.
go back to reference Li Y-H, et al. Molecular characteristics, functions, and related pathogenicity of MERS-CoV proteins. Engineering. 2019;5(5):940–7.CrossRef Li Y-H, et al. Molecular characteristics, functions, and related pathogenicity of MERS-CoV proteins. Engineering. 2019;5(5):940–7.CrossRef
13.
go back to reference Song Z, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11:1. Song Z, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11:1.
14.
go back to reference Corman VM, et al. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163–88.CrossRef Corman VM, et al. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163–88.CrossRef
15.
go back to reference Lei L, et al. Attenuation of mouse hepatitis virus by deletion of the LLRKxGxKG region of Nsp1. PLoS ONE. 2013;8(4):e61166–e61166.CrossRef Lei L, et al. Attenuation of mouse hepatitis virus by deletion of the LLRKxGxKG region of Nsp1. PLoS ONE. 2013;8(4):e61166–e61166.CrossRef
16.
go back to reference Liu DX, et al. Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res. 2014;109:97–109.CrossRef Liu DX, et al. Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res. 2014;109:97–109.CrossRef
17.
go back to reference Gordon DE, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–68.CrossRef Gordon DE, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–68.CrossRef
18.
go back to reference Jauregui AR, et al. Identification of residues of SARS-CoV nsp1 that differentially affect inhibition of gene expression and antiviral signaling. PLoS ONE. 2013;8(4):e62416–e62416.CrossRef Jauregui AR, et al. Identification of residues of SARS-CoV nsp1 that differentially affect inhibition of gene expression and antiviral signaling. PLoS ONE. 2013;8(4):e62416–e62416.CrossRef
19.
go back to reference Wu C, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766–88.CrossRef Wu C, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766–88.CrossRef
20.
go back to reference Tohya Y, et al. Suppression of host gene expression by nsp1 proteins of group 2 bat coronaviruses. J Virol. 2009;83(10):5282–8.CrossRef Tohya Y, et al. Suppression of host gene expression by nsp1 proteins of group 2 bat coronaviruses. J Virol. 2009;83(10):5282–8.CrossRef
21.
go back to reference Narayanan K, et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol. 2008;82(9):4471–9.CrossRef Narayanan K, et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol. 2008;82(9):4471–9.CrossRef
22.
go back to reference Huang C, et al. Alphacoronavirus transmissible gastroenteritis virus nsp1 protein suppresses protein translation in mammalian cells and in cell-free HeLa cell extracts but not in rabbit reticulocyte lysate. J Virol. 2011;85(1):638–43.CrossRef Huang C, et al. Alphacoronavirus transmissible gastroenteritis virus nsp1 protein suppresses protein translation in mammalian cells and in cell-free HeLa cell extracts but not in rabbit reticulocyte lysate. J Virol. 2011;85(1):638–43.CrossRef
23.
go back to reference Lokugamage KG, et al. Severe acute respiratory syndrome coronavirus protein nsp1 is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation. J Virol. 2012;86(24):13598–608.CrossRef Lokugamage KG, et al. Severe acute respiratory syndrome coronavirus protein nsp1 is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation. J Virol. 2012;86(24):13598–608.CrossRef
24.
go back to reference Kamitani W, et al. A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nat Struct Mol Biol. 2009;16(11):1134–40.CrossRef Kamitani W, et al. A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nat Struct Mol Biol. 2009;16(11):1134–40.CrossRef
25.
go back to reference Thoms, M., et al., Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. bioRxiv, 2020: p. 2020.05.18.102467. Thoms, M., et al., Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. bioRxiv, 2020: p. 2020.05.18.102467.
26.
go back to reference Huang C, et al. SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage. PLoS Pathog. 2011;7(12):e1002433.CrossRef Huang C, et al. SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage. PLoS Pathog. 2011;7(12):e1002433.CrossRef
27.
go back to reference Katoh K, Rozewicki J, Yamada KD. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. Brief Bioinform. 2019;20(4):1160–6.CrossRef Katoh K, Rozewicki J, Yamada KD. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. Brief Bioinform. 2019;20(4):1160–6.CrossRef
28.
go back to reference Altschul SF, et al. Basic local alignment search tool. J Mol Biol. 1990;215(3):403–10.CrossRef Altschul SF, et al. Basic local alignment search tool. J Mol Biol. 1990;215(3):403–10.CrossRef
29.
go back to reference Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5(4):725–38.CrossRef Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5(4):725–38.CrossRef
30.
go back to reference Schrodinger, LLC, The PyMOL Molecular Graphics System, Version 1.3r1. 2010. Schrodinger, LLC, The PyMOL Molecular Graphics System, Version 1.3r1. 2010.
31.
go back to reference Almeida MS, et al. Novel beta-barrel fold in the nuclear magnetic resonance structure of the replicase nonstructural protein 1 from the severe acute respiratory syndrome coronavirus. J Virol. 2007;81(7):3151–61.CrossRef Almeida MS, et al. Novel beta-barrel fold in the nuclear magnetic resonance structure of the replicase nonstructural protein 1 from the severe acute respiratory syndrome coronavirus. J Virol. 2007;81(7):3151–61.CrossRef
32.
go back to reference Brockway SM, Denison MR. Mutagenesis of the murine hepatitis virus nsp1-coding region identifies residues important for protein processing, viral RNA synthesis, and viral replication. Virology. 2005;340(2):209–23.CrossRef Brockway SM, Denison MR. Mutagenesis of the murine hepatitis virus nsp1-coding region identifies residues important for protein processing, viral RNA synthesis, and viral replication. Virology. 2005;340(2):209–23.CrossRef
33.
go back to reference Vijgen L, et al. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol. 2005;79(3):1595–604.CrossRef Vijgen L, et al. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol. 2005;79(3):1595–604.CrossRef
34.
go back to reference Farsani SMJ, et al. The first complete genome sequences of clinical isolates of human coronavirus 229E. Virus Genes. 2012;45(3):433–9.CrossRef Farsani SMJ, et al. The first complete genome sequences of clinical isolates of human coronavirus 229E. Virus Genes. 2012;45(3):433–9.CrossRef
35.
go back to reference Holland LA, et al. An 81-nucleotide deletion in SARS-CoV-2 ORF7a identified from sentinel surveillance in Arizona (January to March 2020). J Virol. 2020;94:14.CrossRef Holland LA, et al. An 81-nucleotide deletion in SARS-CoV-2 ORF7a identified from sentinel surveillance in Arizona (January to March 2020). J Virol. 2020;94:14.CrossRef
36.
go back to reference Bal A, et al. Molecular characterization of SARS-CoV-2 in the first COVID-19 cluster in France reveals an amino acid deletion in nsp2 (Asp268del). Clin Microbiol Infect. 2020;26(7):960–2.CrossRef Bal A, et al. Molecular characterization of SARS-CoV-2 in the first COVID-19 cluster in France reveals an amino acid deletion in nsp2 (Asp268del). Clin Microbiol Infect. 2020;26(7):960–2.CrossRef
39.
go back to reference Benedetti F, et al. SARS-CoV-2: march toward adaptation. J Med Virol. 2020;12:1–3. Benedetti F, et al. SARS-CoV-2: march toward adaptation. J Med Virol. 2020;12:1–3.
Metadata
Title
Emerging of a SARS-CoV-2 viral strain with a deletion in nsp1
Authors
Francesca Benedetti
Greg A. Snyder
Marta Giovanetti
Silvia Angeletti
Robert C. Gallo
Massimo Ciccozzi
Davide Zella
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2020
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-020-02507-5

Other articles of this Issue 1/2020

Journal of Translational Medicine 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine